|
Marcus' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: FDA tightens scrutiny of foreign trial data, clears a first pediatric gene therapy trial, and Ultragenyx’s Angelman syndrome drug fails Phase 3.
The top 10 stories from Wed Sep 2, 2026 06:49 AM to Thu Sep 3, 2026 06:49 AM
Generated September 3, 2026 at 6:49 AM
|
|
|
#1 FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease Published 2026-09-02 The FDA allowed the first gene therapy clinical trial for children with ultra-rare Mucolipidosis Type IV, according to the ML4 Foundation. Covered by: prnewswire.com |
#2 STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial Published 2026-09-02 Ultragenyx said its experimental Angelman syndrome therapy GTX-102 showed no benefit over placebo in a Phase 3 trial, disappointing patients, advocates, and investors. Covered by: statnews.com, endpoints.news |
#3 UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease Published 2026-09-02 uniQure filed applications seeking U.S. and UK approval for AMT-130, a gene therapy for Huntington’s disease; FDA priority review could enable approval in Q2 2027. Covered by: biospace.com, endpoints.news, biopharmadive.com, statnews.com |
#4 FDA leaders project enhanced scrutiny of foreign data Published 2026-09-02 FDA leaders are strengthening oversight of foreign clinical-trial data, amid concerns from lawmakers and industry about China’s expanding role in drug research. Covered by: endpoints.news, biospace.com |
#5 Novartis CAR-T deaths raise questions over acceptable autoimmune risk Published 2026-09-02 Three deaths disclosed in Novartis clinical trials have raised concerns about the risks of using CAR-T cell therapies to treat autoimmune diseases. Covered by: endpoints.news |
#6 Capricor, Replimune illustrate why FDA must listen to rare disease specialists Published 2026-09-03 FDA advisory committee meetings for Capricor Therapeutics and Replimune highlighted differing patient outcomes and renewed calls for greater specialization in agency reviews. Covered by: biospace.com |
#7 Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies Published 2026-09-02 Typewriter raised $56 million to develop jumping-gene technology for delivering full genes in humans and creating in vivo CAR-T therapies without viral vectors. Covered by: endpoints.news |
#8 K2 Therapeutics: Spreading bets across range of Asia-sourced assets Published 2026-09-03 K2 Therapeutics, led by former Legend CEO Ying Huang, is seeking a $250 million Series A to develop a diversified portfolio of Asia-sourced assets. Covered by: biocentury.com |
#9 China deaths reignite debate about using viruses to deliver CRISPR therapies Published 2026-09-02 Deaths of two children who received CRISPR therapies in China have renewed US scientists’ concerns about the risks of viral delivery systems in genetic medicines. Covered by: endpoints.news |
#10 Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era Published 2026-09-02 Biotech executives are adjusting pipeline sequencing, capital allocation, partnerships, and FDA engagement amid uncertainty from leadership changes, enforcement shifts, and evolving approval policies. Covered by: genengnews.com |
